腹膜透析治疗130例慢性肾脏病CKD5期患者的临床效果评价
|
摘要
目的探究130例慢性肾脏病CKD5期患者应用腹膜透析治疗的临床疗效。方法 2017年1月—2018年1月为该次研究时段,方便选取130例该院在研究时段内收治的慢性肾脏病CKD5期患者作为研究目标,采用计算机随机分组法,将研究目标分为对照组、治疗组,每组样本均65例,血液透析治疗措施应用于对照中,腹膜透析治疗措施应用于治疗组中,分析两组治疗总有效率、 C反应蛋白水平、营养指标、临床指标。结果治疗组治疗总有效率95.4%高于对照组81.5%(χ~2=6.104,P=0.013);治疗6个月后C反应蛋白水平治疗组(13.64±3.17)mg/L低于对照组(23.44±3.51)mg/L(t=16.705,P=0.000);相较于对照组,营养指标、临床指标治疗组较优(P<0.05)。结论腹膜透析治疗措施应用于慢性肾脏病CKD5期患者中,既可改善临床指标及营养水平,又可降低C反应蛋白水平、提高治疗总有效率,临床应用效果显著,值得临床推广。
Objective To explore the clinical effect of peritoneal dialysis in 130 patients with CKD5 chronic kidney disease.Methods From January 2017 to January 2018, 130 patients with CKD5 chronic kidney disease admitted to our hospital during the study period were convenient divided into control group and treatment group by computer random grouping method.Each group had 65 samples. Hemodialysis treatment measures were applied in the control group. Peritoneal dialysis of treatment measures were applied in the treatment group. The total effective rate of treatment, C-reactive protein level, nutritional indicators, clinical indicators were analyzed. Results The total effective rate of treatment group was 95.4%, which was higher than that of the control group 81.5%(χ~2=6.104, P=0.013). After 6 months of treatment, the C-reactive protein level of the treatment group(13.64±3.17)mg/L was lower than that of the control group(23.44±3.51)mg/L(t=16.705,P=0.000). Compared with the control group, the nutritional index and clinical index in the treatment group were better(P<0.05). Conclusion The application of peritoneal dialysis in CKD5 patients with chronic kidney disease can not only improve the clinical indicators and nutritional level, but also reduce the level of C-reactive protein and improve the total effective rate of treatment. The clinical application effect is remarkable, which is worthy of clinical promotion.
Objective To explore the clinical effect of peritoneal dialysis in 130 patients with CKD5 chronic kidney disease.Methods From January 2017 to January 2018, 130 patients with CKD5 chronic kidney disease admitted to our hospital during the study period were convenient divided into control group and treatment group by computer random grouping method.Each group had 65 samples. Hemodialysis treatment measures were applied in the control group. Peritoneal dialysis of treatment measures were applied in the treatment group. The total effective rate of treatment, C-reactive protein level, nutritional indicators, clinical indicators were analyzed. Results The total effective rate of treatment group was 95.4%, which was higher than that of the control group 81.5%(χ~2=6.104, P=0.013). After 6 months of treatment, the C-reactive protein level of the treatment group(13.64±3.17)mg/L was lower than that of the control group(23.44±3.51)mg/L(t=16.705,P=0.000). Compared with the control group, the nutritional index and clinical index in the treatment group were better(P<0.05). Conclusion The application of peritoneal dialysis in CKD5 patients with chronic kidney disease can not only improve the clinical indicators and nutritional level, but also reduce the level of C-reactive protein and improve the total effective rate of treatment. The clinical application effect is remarkable, which is worthy of clinical promotion.
引文
[1]侯璐蒙,黄燕林,罗怡欣.“5E”康复模式对腹膜透析病人微炎症、营养状态和残余肾功能的影响[J].护理研究,2018,32(6):940-943.
[2]王敏,戴晓霞,吴冰,等.补肾健脾化湿降浊法对腹膜透析患者影响的临床探讨[J].系统医学,2018,3(4):1-2,24.
[3]蒙军平,赵洁,张涵,等.慢性肾脏病患者行透析后能量消耗22例临床研究[J].陕西医学杂志,2018,47(1):23-25.
[4]何锡坤,胡伟文.化瘀益肾方联合腹膜透析对3-4期慢性肾脏病合并颈动脉钙化患者血管内皮损伤ICAM-1、VCAM-1水平的影响[J].四川中医,2017,35(10):91-93.
[5]林建,叶晴,詹林达,等.腹膜透析对慢性肾脏病患者脂联素水平、微炎症及营养状态的影响[J].浙江医学,2017,39(13):1084-1087.
[6]顾亚亭,陈洪宇.陈洪宇治疗慢性肾脏病5期非透析期经验[J].浙江中医药大学学报,2017,41(8):692-695.
[7]杨帆,陈瑾,李贵森.维持性腹膜透析对终末期肾病钙磷代谢的影响[J].实用医院临床杂志,2015,12(4):171-173.
[8]李冰心,杨林,夏敬彪.左卡尼汀在持续性腹膜透析患者中的应用效果观察[J].海南医学,2015,26(10):1504-1506.
[9]张浩,张耀.缺血修饰清蛋白在血液透析患者主要不良心血管事件预测中的应用[J].现代医药卫生,2018,34(4):497-499.
[10]盛亚楠,赵东明,马千里,等.慢性肾脏疾病患者心外膜脂肪体积与冠状动脉钙化的相关性研究[J].中华心血管病杂志,2017,45(2):121-125.
[11]柴璐,胡宏,余堂宏,等.糖尿病肾病(CKD5期)患者血糖控制水平对肾性贫血影响及相关因素分析[J].糖尿病新世界,2017,20(11):182-183.
[12]邹汉良,杜玉开,杨娟.人血清附睾蛋白4诊断卵巢癌的相关影响因素分析[J].中国妇幼保健,2017,30(4):671-675.
[13]胡振奋,黄蔚霞,吴睿轩,等.补肾泄浊法对慢性肾脏病3-5期患者中医证候及矿物质骨代谢的影响[J].中国中医急症,2017,26(11):2011-2014.
[14]蒋红樱,窦丽娜,廖云娟,等.心肌损伤标记物对慢性肾脏病非透析患者评估心脏结构功能的预测[J].昆明医科大学学报,2017,38(10):50-54.
[15]李红波,王小琴,熊飞,等.肾衰合剂联合复方ɑ-酮酸对慢性肾脏病5期维持性腹膜透析患者营养状况的影响[J].湖北中医药大学学报,2016,18(3):68-70.
[2]王敏,戴晓霞,吴冰,等.补肾健脾化湿降浊法对腹膜透析患者影响的临床探讨[J].系统医学,2018,3(4):1-2,24.
[3]蒙军平,赵洁,张涵,等.慢性肾脏病患者行透析后能量消耗22例临床研究[J].陕西医学杂志,2018,47(1):23-25.
[4]何锡坤,胡伟文.化瘀益肾方联合腹膜透析对3-4期慢性肾脏病合并颈动脉钙化患者血管内皮损伤ICAM-1、VCAM-1水平的影响[J].四川中医,2017,35(10):91-93.
[5]林建,叶晴,詹林达,等.腹膜透析对慢性肾脏病患者脂联素水平、微炎症及营养状态的影响[J].浙江医学,2017,39(13):1084-1087.
[6]顾亚亭,陈洪宇.陈洪宇治疗慢性肾脏病5期非透析期经验[J].浙江中医药大学学报,2017,41(8):692-695.
[7]杨帆,陈瑾,李贵森.维持性腹膜透析对终末期肾病钙磷代谢的影响[J].实用医院临床杂志,2015,12(4):171-173.
[8]李冰心,杨林,夏敬彪.左卡尼汀在持续性腹膜透析患者中的应用效果观察[J].海南医学,2015,26(10):1504-1506.
[9]张浩,张耀.缺血修饰清蛋白在血液透析患者主要不良心血管事件预测中的应用[J].现代医药卫生,2018,34(4):497-499.
[10]盛亚楠,赵东明,马千里,等.慢性肾脏疾病患者心外膜脂肪体积与冠状动脉钙化的相关性研究[J].中华心血管病杂志,2017,45(2):121-125.
[11]柴璐,胡宏,余堂宏,等.糖尿病肾病(CKD5期)患者血糖控制水平对肾性贫血影响及相关因素分析[J].糖尿病新世界,2017,20(11):182-183.
[12]邹汉良,杜玉开,杨娟.人血清附睾蛋白4诊断卵巢癌的相关影响因素分析[J].中国妇幼保健,2017,30(4):671-675.
[13]胡振奋,黄蔚霞,吴睿轩,等.补肾泄浊法对慢性肾脏病3-5期患者中医证候及矿物质骨代谢的影响[J].中国中医急症,2017,26(11):2011-2014.
[14]蒋红樱,窦丽娜,廖云娟,等.心肌损伤标记物对慢性肾脏病非透析患者评估心脏结构功能的预测[J].昆明医科大学学报,2017,38(10):50-54.
[15]李红波,王小琴,熊飞,等.肾衰合剂联合复方ɑ-酮酸对慢性肾脏病5期维持性腹膜透析患者营养状况的影响[J].湖北中医药大学学报,2016,18(3):68-70.